Literature DB >> 11684819

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.

R Göke1, A Göke, B Göke, W S El-Deiry, Y Chen.   

Abstract

BACKGROUND/AIMS: We investigated the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone on growth and TRAIL-induced apoptosis in carcinoid cells.
METHODS: Carcinoid cells were incubated without and with pioglitazone. Effects on growth were examined by cell count and cell cycle analysis. p21waf1/cip1 expression was determined by Western blotting. Cytotoxicity assay was performed by FACS analysis.
RESULTS: Pioglitazone suppressed the growth and induced apoptosis of carcinoid cells. Additionally, pioglitazone significantly enhanced carcinoid cell death induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). The enhancement of TRAIL-induced apoptosis was associated with an upregulation of cyclin-dependent kinase inhibitor p21waf1/cip1 in pioglitazone-treated carcinoid cells. Importantly, overexpression of p21waf1/cip1 in carcinoid cells by adenoviral gene transfer of p21 sensitized them to TRAIL-induced apoptosis.
CONCLUSIONS: These results suggest that pioglitazone inhibits cell growth and sensitizes cells to TRAIL-induced apoptosis by induction of p21waf1/cip1. Therefore, pioglitazone can be an effective therapeutic adjuvant for the treatment of carcinoid tumors. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684819     DOI: 10.1159/000048843

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  10 in total

1.  The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation.

Authors:  Koen M A Dreijerink; Radhika A Varier; Olivier van Beekum; Ellen H Jeninga; Jo W M Höppener; Cornelis J M Lips; J Alain Kummer; Eric Kalkhoven; H T Marc Timmers
Journal:  Mol Cell Biol       Date:  2009-07-13       Impact factor: 4.272

2.  Loss of p21Waf1/Cip1/Sdi1 enhances intestinal stem cell survival following radiation injury.

Authors:  Robert J George; Mark A Sturmoski; Randal May; Sripathi M Sureban; Brian K Dieckgraefe; Shrikant Anant; Courtney W Houchen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

Review 3.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

Review 4.  Genes and genomics of autoimmune inflammation: from Rel to TRAIL.

Authors:  Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Authors:  Michael J Pishvaian; John L Marshall; Andrew J Wagner; Jimmy J Hwang; Shakun Malik; Ion Cotarla; John F Deeken; A Ruth He; Hirut Daniel; Abdel-Baset Halim; Hamim Zahir; Catherine Copigneaux; Kejian Liu; Robert A Beckman; George D Demetri
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

6.  A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation.

Authors:  Jessica Castro; Marc Ribó; Susanna Navarro; Maria Victòria Nogués; Maria Vilanova; Antoni Benito
Journal:  BMC Cancer       Date:  2011-01-11       Impact factor: 4.430

7.  Investigation of the antibacterial activity of pioglitazone.

Authors:  Majed M Masadeh; Nizar M Mhaidat; Sayer I Al-Azzam; Karem H Alzoubi
Journal:  Drug Des Devel Ther       Date:  2011-09-27       Impact factor: 4.162

8.  Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy.

Authors:  Hyunju Park; Si Hwan Ko; Jae Myun Lee; Jeon Han Park; Youn Hee Choi
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

9.  Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.

Authors:  Marie-Laure Plissonnier; Sylvie Fauconnet; Hugues Bittard; Christiane Mougin; Jean Rommelaere; Isabelle Lascombe
Journal:  Oncotarget       Date:  2017-11-22

10.  PPARgamma and Apoptosis in Cancer.

Authors:  Heath A Elrod; Shi-Yong Sun
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.